Larry Park
CHDI Foundation
55 Papers
320 Citations
Larry Park is an academic researcher from CHDI Foundation. The author has contributed to research in topics: Huntington's disease & Oxidative stress. The author has an hindex of 29, co-authored 55 publications. Previous affiliations of Larry Park include Princeton University & Cornell University.
Chat about Author
Papers
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175
Liliana B. Menalled,Andrea E. Kudwa,Samuel I. Miller,Jon Fitzpatrick,Judy Watson-Johnson,Nicole Keating,Melinda C Ruiz,Richard Mushlin,William Alosio,Kristi McConnell,David A. Connor,Carol Murphy,Steve Oakeshott,Mei Kwan,Jose Beltran,Afshin Ghavami,Dani Brunner,Larry Park,Sylvie Ramboz,David Howland +19 more
TL;DR: A new mouse line, the zQ175 knock-in mouse, derived from a spontaneous expansion of the CAG copy number in the authors' CAG 140 knock- in colony is described, which carries a significantly higher CAG repeat length and is expected to be more significantly impaired than the parent line.
467
Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models
Liliana B. Menalled,Bassem F. El-Khodor,Monica Patry,Mayte Suárez-Fariñas,Samantha J. Orenstein,Benjamin Zahasky,Christina Leahy,Vanessa C. Wheeler,X. William Yang,Marcy E. MacDonald,A. Jennifer Morton,GP Bates,Janet M. Leeds,Larry Park,David Howland,Ethan Signer,Allan J. Tobin,Daniela Brunner +17 more
TL;DR: This first extensive standardized cross-characterization of several HD animal models under standardized conditions highlights several behavioral outcomes, such as hypoactivity, amenable to standardized preclinical therapeutic drug screening.
340
Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease
Taneli Heikkinen,Kimmo Lehtimäki,Nina Vartiainen,Jukka Puoliväli,Susan J. Hendricks,Jacob R. Glaser,Amyaouch Bradaia,Kristian Wadel,Chrystelle Touller,Outi Kontkanen,Juha Yrjänheikki,Bruno Buisson,David Howland,Vahri Beaumont,Ignacio Munoz-Sanjuan,Larry Park +15 more
TL;DR: The zQ175 KI model has robust behavioral, electrophysiological, and histopathological features that may be valuable in both furthering the understanding of HD-like pathophyisology and the evaluation of potential therapeutic strategies to slow the progression of disease.
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
Bryan Zeitler,Steven Froelich,Kimberly Marlen,David A. Shivak,Qi Yu,Davis Li,Jocelynn R. Pearl,Jeffrey C. Miller,Lei Zhang,David Paschon,Sarah J. Hinkley,Irina Ankoudinova,Stephen Lam,Dmitry Guschin,Lexi Kopan,Jennifer M. Cherone,Hoang Oanh B. Nguyen,Guijuan Qiao,Yasaman Ataei,Matthew C. Mendel,Rainier Amora,Richard T. Surosky,Josee Laganiere,B. Joseph Vu,Anand Narayanan,Yalda Sedaghat,Karsten Tillack,Christina Thiede,Annette Gärtner,Seung Kwak,Jonathan Bard,Ladislav Mrzljak,Larry Park,Taneli Heikkinen,Kimmo Lehtimäki,Marie Svedberg,Jenny Haggkvist,Lenke Tari,Miklós Tóth,Andrea Varrone,Christer Halldin,Andrea E. Kudwa,Sylvie Ramboz,Michelle Day,Jyothisri Kondapalli,D. James Surmeier,Fyodor D. Urnov,Philip D. Gregory,Edward J. Rebar,Ignacio Munoz-Sanjuan,H. Steve Zhang +50 more
TL;DR: Improvements in a range of molecular, histopathological, electrophysiological and functional endpoints are demonstrated and support the continued development of an allele-selective ZFP-TF for the treatment of Huntington’s disease.
187
HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration
Michal Mielcarek,Christian Landles,Andreas Weiss,Amyaouch Bradaia,Tamara Seredenina,Linda Inuabasi,Georgina F. Osborne,Kristian Wadel,Chrystelle Touller,Rachel Butler,Rachel Butler,Janette Robertson,Sophie A. Franklin,Donna L. Smith,Larry Park,Paul A. Marks,Erich E. Wanker,Eric N. Olson,Ruth Luthi-Carter,Herman van der Putten,Vahri Beaumont,Gillian P. Bates +21 more
TL;DR: Reduction of HDAC4 levels in mouse models of Huntington's disease delays cytoplasmic aggregation in the brain and improves the molecular pathology of HD, providing a potential new therapeutic target.